This transcript has been edited for clarity.
Hello. I'm Dr Jeffrey Weber. I'm a medical oncologist and deputy director of the Laura and Isaac Perlmutter Cancer Center at New York University Langone Health in New York City. Today I'll be commenting on two studies on melanoma treatment presented at the oral sessions of this year's American Society of Clinical Oncology (ASCO) meeting.
RELATIVITY-047 was a randomized study that included more than 700 patients with previously untreated melanoma. Patients were randomly assigned to receive either relatlimab (RELA), an antibody that blocks the lymphocyte activation gene 3 (LAG-3), plus nivolumab (NIVO) vs NIVO alone. The primary endpoint of this trial was investigator-called progression-free survival (PFS). The secondary endpoints were response rate and overall survival.
This was a well-conducted, well-balanced, randomized phase 3 trial. All of the usual prognostic factors were well matched, including gender, age, performance status, serum LDH, tumor burden, and LAG-3 expression. Previous trials of second-line treatment have shown that a high LAG-3 expression in the tumor was associated with a better response. Overall, 75% of the patients in this study had LAG-3 in more than 1% of the tumor, presumably mostly on infiltrating immune cells, with 25% having LAG-3 in less than 1%, probably meaning that they were essentially LAG-3 negative.
COMMENTARY
NIVO + LAG-3 Antibody Succeeds in Advanced Melanoma
Jeffrey S. Weber, MD, PhD
DisclosuresJuly 01, 2021
This transcript has been edited for clarity.
Hello. I'm Dr Jeffrey Weber. I'm a medical oncologist and deputy director of the Laura and Isaac Perlmutter Cancer Center at New York University Langone Health in New York City. Today I'll be commenting on two studies on melanoma treatment presented at the oral sessions of this year's American Society of Clinical Oncology (ASCO) meeting.
RELATIVITY-047 was a randomized study that included more than 700 patients with previously untreated melanoma. Patients were randomly assigned to receive either relatlimab (RELA), an antibody that blocks the lymphocyte activation gene 3 (LAG-3), plus nivolumab (NIVO) vs NIVO alone. The primary endpoint of this trial was investigator-called progression-free survival (PFS). The secondary endpoints were response rate and overall survival.
This was a well-conducted, well-balanced, randomized phase 3 trial. All of the usual prognostic factors were well matched, including gender, age, performance status, serum LDH, tumor burden, and LAG-3 expression. Previous trials of second-line treatment have shown that a high LAG-3 expression in the tumor was associated with a better response. Overall, 75% of the patients in this study had LAG-3 in more than 1% of the tumor, presumably mostly on infiltrating immune cells, with 25% having LAG-3 in less than 1%, probably meaning that they were essentially LAG-3 negative.
Medscape Oncology © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Jeffrey S. Weber. NIVO + LAG-3 Antibody Succeeds in Advanced Melanoma - Medscape - Jul 01, 2021.
Tables
Authors and Disclosures
Authors and Disclosures
Author(s)
Jeffrey S. Weber, MD, PhD
Professor of Medicine, Deputy Director, Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY
Disclosure: Jeffrey S. Weber, MD, PhD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Bristol-Myers Squibb Company; GlaxoSmithKline; Genentech BioOncology; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; EMD Serono, Inc.; Celldex Therapeutics; CytomX Therapeutics; Nektar Therapeutics; Roche; Altor BioScience Corporation; Daiichi-Sankyo; Eli Lilly & Company
Received income in an amount equal to or greater than $250 from: Bristol-Myers Squibb Company; GlaxoSmithKline; Genentech BioOncology; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; EMD Serono, Inc.; Celldex Therapeutics; CytomX Therapeutics; Nektar Therapeutics; Roche; Altor BioScience Corporation; Daiichi-Sankyo; Eli Lilly & Company
Patent: Named on a patent filed by Moffitt for a biomarker for ipilimumab; Named on a patent filed by Biodesix for a biomarker for nivolumab